Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for ImmunotherapyDaiichi Sankyo2026-07-31 08:40:18Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line
-
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2026-07-24 12:32:03Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with
-
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid TumorsDaiichi Sankyo2026-06-30 16:06:21Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for
-
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for ImmunotherapyDaiichi Sankyo2026-06-30 16:03:43Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic
-
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid TumorsDaiichi Sankyo2026-06-09 12:59:47Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive
-
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast CancerDaiichi Sankyo2026-02-19 09:46:13ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with
-
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2026-01-19 10:21:05ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients
-
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern EuropeDaiichi Sankyo2026-01-08 18:23:36Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and
-
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for ImmunotherapyDaiichi Sankyo2026-01-08 18:09:17DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with
-
ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid TumorsDaiichi Sankyo2025-09-11 14:39:48ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive
